ImmuPharma PLC
  • Announcements
  • About Us
    • About Us
    • Our Team
    • Board of Directors
  • Our Science
    • Our Science
    • ImmuPharma Biotech
    • Key Clinical Investigators
  • Pipeline
    • Pipeline
    • Autoimmunity & Inflammation
    • Anti-Infectives
  • Partnerships & Collaborations
  • Investors
    • Investors
    • AIM Rule 26 Information
    • Regulatory News
    • Corporate Governance
    • Board of Directors
    • Annual Reports
    • Analyst Research
    • Interviews
    • Professional advisers
    • Email Alerts
  • Contact
Archives
  • 2025
  • 2024
  • 2023
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
  • 2014
  • 2013
  • 2012
  • 2011
November 28, 2017

Update on Lupuzor™ Pivotal Phase III Study

Read More
November 28, 2017

ImmuPharma PLC (“ImmuPharma” or the “Company”) Holding(s) in Company

Read More
November 06, 2017

Successful Completion of Lanstead Sharing Agreement

Read More
September 27, 2017

Interim Results Announcement for the six months ended 30 June 2017

Read More
September 27, 2017

ImmuPharma initiates preparation of Lupuzor’s™ regulatory submissions

Read More
September 21, 2017

Update on Lupuzor™ Pivotal Phase III Study

Read More
July 03, 2017

2017 Annual General Meeting – All Resolutions Passed

Read More
June 30, 2017

Annual General Meeting and Investor Presentation

Read More
June 07, 2017

Notice of Annual General Meeting on 30 June 2017 at 10.30am

Read More
June 06, 2017

Final Results Announcement for the twelve months ended 31 December 2016

Read More
May 24, 2017

Notification of full year results – 1st June 2017

Read More
May 18, 2017

Update on Lupuzor™ Pivotal Phase III Study

Read More
  • 1
  • 2
  • Keep up-to-date with email alerts

  • @immupharma

Aim Rule 26 Contact informationDisclaimerPrivacy PolicySite map

© ImmuPharma PLC 2005-2022 | All rights reserved